![](https://synapseconsortium.com/wp-content/uploads/2023/04/Fusion-Pharmaceuticals-320x184.png)
0 comments / 0 votes
This press release was originally published by Fusion Pharmaceuticals on April 12, 2023. Read the original post here. FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tumor Cells HAMILTON, ON and BOSTON, April 12, 2023 /– Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision […]
0 comments / 0 votes
![](https://synapseconsortium.com/wp-content/uploads/2022/09/Smart-Site-Selection-Life-Sciences-320x184.jpg)
0 comments / 0 votes
23
Sep-2022
Sep-2022
Making a smart site selection could drive the commercialization of your intellectual property. Here are three examples that are helping to make Hamilton, Ontario, the next leader in life sciences research and commercialization.
0 comments / 0 votes